Key terms

About NKTX

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NKTX news

Mar 28 4:48pm ET Nkarta director buys $20M in common stock Mar 26 2:59pm ET Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-Hearted Mar 26 7:25am ET TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX) Mar 25 10:05pm ET Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX) Mar 25 6:42am ET Nkarta prices 21M shares at $10.00 in underwritten offering Mar 25 6:22am ET Nkarta’s NKX019 Shows Potential in Lymphoma Treatment Mar 24 9:27pm ET Nkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy Rating Mar 22 9:40am ET Nkarta trading resumes Mar 22 9:35am ET Nkarta trading halted, volatility trading pause Mar 22 7:10am ET Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY) Mar 22 6:48am ET Nkarta price target lowered to $25 from $31 at Mizuho Mar 22 6:45am ET Nkarta’s Strategic Pivot to NKX019 Spurs Buy Rating Amid Strong Financials and Promising Trial Prospects Mar 22 6:27am ET Nkarta’s Strategic Focus and Financial Strength Underpin Buy Rating Mar 22 6:26am ET Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment Mar 22 4:43am ET Nkarta downgraded to Outperform from Strong Buy at Raymond James Mar 21 4:06pm ET Nkarta: cash sufficient to fund current operating plan into 2026 Mar 21 4:05pm ET Nkarta reports Q4 EPS (57c), consensus (59c) Mar 21 2:35pm ET Nkarta options imply 10.4% move in share price post-earnings Mar 19 1:38am ET Innovative NK-Cell Therapy: A Buy Rating for Nkarta’s Groundbreaking Approach to Autoimmune Diseases Mar 04 9:13am ET Nkarta price target raised to $31 from $9 at Mizuho Feb 18 11:47pm ET Leerink Partners Keeps Their Buy Rating on Nkarta (NKTX) Jan 17 12:27am ET 3 Best Stocks to Buy Now, 1/17/2024, According to Top Analysts Jan 11 1:34am ET Nkarta’s Promising CAR-NK Cell Therapies: A ‘Buy’ Rating Reinforced by Robust Clinical Data and Strategic Advancements Jan 11 1:31am ET Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX) Jan 09 7:36am ET Stifel Nicolaus Sticks to Its Buy Rating for Nkarta (NKTX) Jan 09 5:55am ET Buy Rating for Nkarta’s Stock Backed by Promising CAR-NK Therapy Developments and Strategic Advantages Jan 08 3:35pm ET Buy Rating Reiterated for Nkarta Amid Promising Redosing Results and Broad Therapeutic Potential

No recent news articles are available for NKTX

No recent press releases are available for NKTX

NKTX Financials

1-year income & revenue

Key terms

NKTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NKTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms